HPSE2
Basic information
Region (hg38): 10:98457077-99235862
Previous symbols: [ "UFS" ]
Links
Phenotypes
GenCC
Source:
- urofacial syndrome type 1 (Definitive), mode of inheritance: AR
- urofacial syndrome type 1 (Moderate), mode of inheritance: AR
- Ochoa syndrome (Supportive), mode of inheritance: AR
- urofacial syndrome type 1 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Ochoa syndrome; Urofacial syndrome 1 | AR | Renal | Individuals are at high risk of infantile-onset vesicoureteral reflux leading to kidney damage, hypertension, and eventual renal failure, and surveillance and preventive measures related to manifestations such as urinary tract/renal infections may be beneficial | Craniofacial; Neurologic; Renal | 11446407; 19839856; 19669792; 20560209; 20560210; 20605127; 21332471; 21450525 |
ClinVar
This is a list of variants' phenotypes submitted to
- Urofacial_syndrome_type_1 (99 variants)
- not_provided (89 variants)
- Inborn_genetic_diseases (76 variants)
- HPSE2-related_disorder (11 variants)
- Ochoa_syndrome (3 variants)
- Congenital_anomaly_of_kidney_and_urinary_tract (2 variants)
- not_specified (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HPSE2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000021828.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 25 | 29 | ||||
missense | 137 | 144 | ||||
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 9 | |||||
splice donor/acceptor (+/-2bp) | 6 | |||||
Total | 9 | 12 | 141 | 30 | 2 |
Highest pathogenic variant AF is 0.000419418
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HPSE2 | protein_coding | protein_coding | ENST00000370552 | 12 | 776745 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000151 | 0.998 | 125670 | 0 | 78 | 125748 | 0.000310 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.245 | 316 | 329 | 0.962 | 0.0000189 | 3822 |
Missense in Polyphen | 122 | 135.08 | 0.90319 | 1580 | ||
Synonymous | -0.814 | 144 | 132 | 1.09 | 0.00000677 | 1224 |
Loss of Function | 2.79 | 11 | 26.5 | 0.415 | 0.00000136 | 327 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000579 | 0.000579 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000945 | 0.0000924 |
European (Non-Finnish) | 0.000520 | 0.000519 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000654 | 0.0000653 |
Other | 0.000490 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Binds heparin and heparan sulfate with high affinity, but lacks heparanase activity. Inhibits HPSE, possibly by competing for its substrates (in vitro). {ECO:0000269|PubMed:20576607}.;
- Disease
- DISEASE: Urofacial syndrome 1 (UFS1) [MIM:236730]: A rare autosomal recessive disorder characterized by facial grimacing when attempting to smile and failure of the urinary bladder to void completely despite a lack of anatomical bladder outflow obstruction or overt neurological damage. Affected individuals often have reflux of infected urine from the bladder to the upper renal tract, with a risk of kidney damage and renal failure. {ECO:0000269|PubMed:20560209, ECO:0000269|PubMed:20560210}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Proteoglycans in cancer - Homo sapiens (human);Glycosaminoglycan degradation - Homo sapiens (human);Metabolism of carbohydrates;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Glycosaminoglycan metabolism;Metabolism
(Consensus)
Recessive Scores
- pRec
- 0.185
Intolerance Scores
- loftool
- 0.898
- rvis_EVS
- 0.09
- rvis_percentile_EVS
- 60.57
Haploinsufficiency Scores
- pHI
- 0.297
- hipred
- N
- hipred_score
- 0.454
- ghis
- 0.455
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.303
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hpse2
- Phenotype
- growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); digestive/alimentary phenotype; renal/urinary system phenotype;
Gene ontology
- Biological process
- glycosaminoglycan catabolic process;biological_process;positive regulation of cell population proliferation;extracellular matrix organization
- Cellular component
- plasma membrane;extracellular matrix
- Molecular function
- heparanase activity;heparan sulfate proteoglycan binding